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Neuroblastoma (NB) is an extracranial tumor that affects the nervous 
system and accounts for approximately 650 – 800 cases diagnosed per year in 
children under the age of 5 (www.cancer.org/cancer/neuroblastoma/about/key-
statistics.html). NB occurs at a relatively rare rate of 10.2 per million children 
under 15 years old but accounts for 12-15% of pediatric cancer death because 
patients with high-risk NB (HRNB) have 5-year survival rates between 40-
50%(Brodeur, 2003; Park et al. 2010). Developmental biology research has 
recognized neural crest cells (NCC) as the progenitor cells of NB, as tumors form 
in the trunk NC derived sympathetic nervous system (Dupin, 2013; Simões-Costa 
et al., 2015). Genome-wide association studies (GWAS) of these tumors reveal 
several chromosomal aberrations and genes related to the development of NB 
(Pugh et al., 2013; Seeger et al., 1985). Unfortunately, the heterogeneity of the 
disease has revealed a low mutation frequency in suspected oncogenes, along 
with an assortment of chromosomal gains and losses, resulting in a variety of 
mechanisms of NB formation. These structural features demonstrate the 
complexity of NB tumorigenesis and the unlikeliness of developing a single target 
treatment (Matthay, K et al., 2012). Amongst all the predictors recognized in NB 
formation, amplification of the MYCN gene occurs in 20% of tumors and serves 
as the most significant prognosticator of poor outcomes in HRNB patients 
(Brodeur, 1984). These insights have resulted in NCC experiments in mice, 





overexpression of MYCN and other oncogenes such as ALK and LMO1(Weiss et 
al.,1997; Zhu et al., 2012; Olsen et al., 2017). While these models have 
elucidated the association of MYCN and LMO1 overexpression in NCC to NB 
formation, they lack a direct descriptive model of NB formation in human NCC.   
Building off the current understanding of genes synergistically driving 
neuroblastoma, I utilized H1 human embryonic stem cells (hESC) to create a cell 
line inducible for LMO1 and MYCN. Through genetic engineering, and 
subcloning, I created two constructs: a plasmid containing the MYCN gene under 
the regulation of the Tetracycline On (TET-ON) system and the LMO1 construct 
under the regulation of TET-ON. I sequenced the constructs, analyzed their 
genetic composition, and found the TET-ON LMO1 suitable for integration into 
the H1 hESC. After nucleofection and genetic screening, the data suggest the 
production of a mixed population of H1 hESC containing a subset of cells that 
appear to have integrated the TET-ON LMO1 into the AAVS1 locus at 
chromosome 19. Further attempts are required for the complete development of 
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NEURAL CREST CELL DEVELOPMENT AND ROLE IN 
 NEUROBLASTOMA 
Overview of Neural Crest Cells 
Neural crest cells (NCC) are a population of multipotent progenitor cells 
that are unique to vertebrates that emerge early in development and migrate 
extensively to form a multitude of derivatives (Prasad et al., 2019). NCC 
differentiates into a variety of cell lineages, such as the sensory neurons and glia 
of the sympathetic and parasympathetic nervous system, hormone-producing 
cells of the adrenal gland, pigment-producing cells, and the connective and 
structural components of the craniofacial region (Simões-Costa, M., & Bronner, 
M. E. 2015). The migratory nature of NCC and their differentiation to a wide 
variety of cell types is accomplished through complex spatial-temporal 
intracellular and intercellular singling. Defects in NCC that produce birth defects 
are classified as neurocristopathies and are responsible for various diseases, 
including cleft lip/palate, Hirschsprung, Waardenburg syndromes, and cancers 
such as melanoma and neuroblastoma (Guillermo et al., 2018). Therefore, to 
understand the progression of neurocristopathy, researchers investigate the early 
development, genetic aberrations, signaling pathways, and cellular environment 






Neural Crest Development 
Neural crest cells are a derivate of the ectoderm and develop during 
neurulation when the neural plate invaginates to form the neural tube. Research 
conducted in chicken and amphibian embryos has demonstrated that neural 
crest induction occurs in a two-step process. The first step involves WNT and 
FGF signaling, which promotes the formation of the neural plate border tissue, 
which flanks the neural plate and separates the neural and nonneural ectoderm. 
The second step of the induction process involves Wnt, BMP, and Notch 
pathways that are responsible for activating and maintaining neural crest cell 
specificity. While the signals responsible for the formation of neural crest cells 
are well characterized. There is much debate on how and what tissues interact in 
neural crest cell formation.  
Neural crest cells develop along most of the dorsal axis of the neural tube 
and exhibit different migration patterns according to the signals received by the 
neural crest cells (Prasad et al., 2019).  The NC has four distinct anatomical 
regions on the neural tube characterized by the derivatives they produce: cranial 
NC, cardiac NC, trunk NC, vagal/sacral NC. The cranial NC migrates to the 
pharyngeal arches and forms the craniofacial skeleton, parasympathetic and 
sensory ganglia, and endocrine and pigment cells (Gilbert, 2000). The cardiac 
NC is a subregion of the cranial NC, which develops into the neurons, cartilage, 
and connective tissues of the pharyngeal arches and the muscular-connective 






dorsal root ganglia, the sympathetic ganglia, and melanocytes. The vagal/sacral 
NC form the parasympathetic ganglia of the gut, and these cell types are 
dispersed along the neural tube.  
 
Trunk Neural Crest Derivatives and Neuroblastoma Formation 
 
NB tumors are localized to the sympathetic nervous system, particularly 
the adrenal medulla has isolated the trunk NC as the population of cells involved 
in tumor formation. The trunk NC has two avenues of migration: the dorsolateral 
and the ventrolateral pathway. The dorsolateral pathway produces skin 
melanocytes, while the ventrolateral pathway produces the dorsal root ganglia, 
sympathetic ganglia, adrenal medulla, and aortic nerve clusters (Gilbert, 2000). It 
is the sympathetic ganglia and specifically the adrenal medulla, that is associated 
with the NB tumor formation. NB tumors are generally localized to one of the 
adrenal glands, but there is a small subset of NB patients that present bilateral 
tumors in both adrenal glands, suggesting NB tumorigenesis before the migration 
of the NC (Pagès et al., 2009). The migratory pattern of NCC, the location of 
tumors in the sympathetic chain, along with single and bilateral adrenal glands, 
















Figure 1. Neural Tube Formation. 
Representation of the Ectoderm, Neural plate borders, and the Neural plate 
before the formation of the neural tube. The bottom portion of the diagram 
depicts the neural tube, neural crest, and ectoderm, which developed after the 









THE GENETICS AND MODELS OF NEUROBLASTOMA 
Neuroblastoma Overview 
The development of a cell line project that can model NB involves 
understanding the molecular and genetic features of the disease. This task 
required investigation into the clinical data of high-risk neuroblastoma patients 
and the emerging genome-wide association studies exploring the genomic and 
genetic structures involved in cancer. Genomic analysis of HRNB tumors has 
revealed the chromosomal aberrations and the genetic interactions that 
correspond to clinically favorable or unfavorable outcomes in patients (Cheung, 
N. K., & Dyer, M. A. 2013). There are two basic patterns of genomic 
modifications that impact NB prognosis. The first being whole chromosomal gain, 
which can produce a positive outcome in NB patients. The second involves 
segmental chromosomal losses, gains, or a combination of both, which results in 
MYCN amplification, loss of tumor suppressor function, or increased expression 
of other oncogenes. The genomic survey of tumors has revealed there is no 
single genetic mutation that corresponds with HRNB and reduced survival rates 
(Pugh TJ). This reality required the Garcia-Castro laboratory to develop a model 









Clinically Observed Chromosomal Aberrations in Neuroblastoma 
 
Deletions in chromosome 1p36 occur in approximately 70% of tumors 
associated with an elevated risk of recurrence in patients (Kim, S. et al., 2006). 
The suspected cause of tumor formation is the loss of CHD5, a tumor suppressor 
gene that regulates the proliferation of cells in the nervous system (Colon, N. C., 
& Chung, D. H., 2011). The whole chromosomal gain of chromosome 17 tends to 
lead to a favorable outcome, but the somatic gain of chromosome 17q manifests 
in over 50% of Neuroblastomas cases correlated with poor survival outcomes 
(Van Roy et al., 2009). Chromosome 17q contains survivin/BIRC5 (an anti-
apoptotic protein) and nm23/NME1 (nucleoside diphosphate kinases), which 
paired with MYCN overexpression lead to tumor growth and proliferation. 
Another recurrent chromosomal aberration that presents a different mechanism 
of NB formation is the somatic loss of chromosome 3q and 11q, which produces 
NB without MYCN overexpression (Van Roy et al., 2009). Chromosomal 
aberrations are indicative of failures of regulatory factors that result from a 
multifaceted loss of apoptotic genes and the gain of proto-oncogenes (Cheung, 
N. K., & Dyer, M. A., 2013. These aberrations have become clinically recognized 










Genes and Modes of Neuroblastoma Inheritance 
 
MYCN belongs to the MYC family of oncogenes, whose deregulation 
appears in a variety of cancers and perhaps are involved in all human tumor 
formation (Dang, 2012). MYCN is located on chromosome 2p24.3 and produces 
the protein N-MYC which is necessary for the proliferation of progenitor cells 
during the development of the central nervous system (Knoepfler et al., 2002). 
MYCN expression is observable in the early neural crest cells, and in typical 
development, expression decreases as neuroblasts differentiate into their 
terminal cell type (Huang, M., & Weiss, W. A., 2013). Overexpression of MYCN 
appears in many cancers of the nervous system as well as nonneuronal tumors 
such as prostate cancers, but MYCN is most notably associated with high-risk 
neuroblastoma and poor prognosis in patients (Beltran et al., 2011; Seeger et al., 
1985).  In approximately 20% of NB tumors, the MYCN gene is amplified, 
presenting between 4 to 10 chromosomal copies (Modak, S., & Cheung, N. K., 
2010). Despite the known oncogenic nature of MYCN in NB, its role as a critical 
transcription factor for development makes it an undesirable target for 
suppression (Kushner B. H. 2004). This reality has motivated researchers to 
identify the down streams pathway of N-MYC or synergistic genes that promote 
NB as possible therapeutic targets. 
Familial NB is inherited in an autosomal dominant manner with incomplete 
penetrance that accounts for approximately 1-2% of all cases of NB (Colon, N. 






than sporadic cases and present many primary tumors and other clinical 
hallmarks associated with NB (Smith, V., & Foster, J. 2018). The inheritance 
pattern is described in the late 1960s due to cases where several siblings in a 
family would develop NB tumors in the sympathetic nervous system (Knudson, A. 
G., Jr, & Strong, L. C., 1972). In the mid to late 2000s, the genes PHOX2B and 
ALK were identified for the role they played in the familial inheritance pattern 
(Trochet et al., 2004; Janoueix-Lerosey et al., 2008). PHOX2B is a gene that 
encodes for a paired homeodomain transcription factor that regulates cell cycle, 
neuronal differentiation, and account for approximately 6-10% of familial cases 
(Mossé et al., 2004). ALK (anaplastic lymphoma kinase) is a gene that encodes a 
tyrosine kinase receptor that plays a role in neuronal differentiation, proliferation, 
survival (Mossé et al., 2008). Genome sequencing has identified several 
mutations in the ALK gene, which are the most aggressive type of familial NB, 
causing mutation resulting in the majority of primary neuroblastoma (Schulte et 
al., 2013). Familial NB, while well-characterized, remains the rarest form of NB, 
and much attention has is focused on the Sporadic formation of NB.  
Sporadic NB is the most typical manner that tumors develop in the 
sympathetic chain, which results from somatic mutations that are not inherited. 
The most common mutation observed in sporadic NB is the gain of the MYCN 
gene copies, which express a high level of N-MYC protein. Genome-wide 
association studies (GWAS) have identified nine other genes involved in the 






HACE1 observed in high-risk tumors (Bosse, K. R., & Maris, J. M., 2016). The 
LIM-domain-only (LMO1) gene, located at 11p15 is implicated across several 
epidemiological studies as an NB oncogene in human tumors (Matthews, J. M., 
Lester, K., Joseph, S., & Curtis, D. J., 2013). The somatic gain of 11p results in 
elevated levels of LMO1 expression, which is detected in tumors that have 
metastasized (Bach, 2000). Experiments demonstrate reducing LMO1 
expression with short hairpin RNA lowered the growth of NB tumors while 
increasing LMO1 promotes tumor formation (Wang K, Diskin SJ, Zhang H, et al. 
2011). The implications of LMO1 expression in HRNB has persuaded 
researchers to develop a model to study its role in NB formation. 
 
Current Models of Neuroblastoma Research 
 
Clinically the overexpression of MYCN has shown an association with 
neuroblastoma in several retroactive studies. However, the demonstration of 
MYCN expression initiating NB formation was absent in the literature (Olsen et 
al., 2017). Researchers established transgenic mice, zebrafish, and primary cell 
models to observe if MYCN overexpression was sufficient to drive NB. The goal 
of MYCN overexpression in a model organism is to promote tumor growth in the 
sympathetic nervous system, particularly the adrenal medulla, to resemble 
human neuroblastoma and identify a possible mechanism of tumorigenesis.  
  One of the first models that demonstrated MYCN's role in NB formation 






NCC. (Weiss et al. 1997). This novel murine model utilized a rat tyrosine 
hydroxylase promoter, and while NB tumors formed, the model was crude as 
MYCN expression was not robust, and strain background affected the level of 
tumor development (Althoff et al. 2015). The transgenic mouse line LSL-MYCN; 
Dbh-iCre (Cre-conditional induction of MYCN in dopamine- β- hydroxylase- 
expressing cells) was created to overcome the lack of robust expression in all 
mice strain (Althoff et al. 2015). The transgenic mice developed tumors with an 
incidence of >75% regardless of the original strain. Specific expression of MYCN 
in the neural crest produced abdominal tumors, which had a histology and 
expression markers typical of human NB (Rickman et al. 2018). Genomic 
analysis of the tumors revealed chromosomal aberrations syntenic to human NB, 
specifically the murine partial gain of 11q, which is homologous to human 
chromosome 17q – A frequent segmental chromosomal gain in human NB 
(Vandesompele et al. 2005). The LSL-MYCN; Dbh-iCre mouse established a 
model of advancing neuroblastoma from MYCN overexpression. This experiment 
makes it plausible that similar results may be repeated in human NCC with 
MYCN overexpression.  
GWAS of HRNB tumors observed an association with LMO1 
concentration and the development of aggressive cancers in human patients 
(Wang K, Diskin SJ, Zhang H, et al. 2011). Researchers interested in the 
influence of the oncogenes LMO1 and MYCN on NB created transgenic 






LMO1 with MYCN (dβh MYCN; LMO1) under a dopamine-β-hydroxylase(dβh) 
gene promoter (Zhu et al., 2017). The authors did not observe tumor formations 
in the cell line dβh LMO1 when LMO1 expression was high in the absence of 
high MCYN expression. The transgenic zebrafish that overexpressed MYCN only 
accrued 20-30% tumor formation within its population, while the double mutant 
dβh MYCN; LMO1 contained 80% tumor formation in its population of zebrafish. 
The experiment showed that high expression of LMO1 when in collaboration with 
high levels of MYCN expression leads to the accelerated onset of NB in vivo 
(Zhu et al., 2017). The finding in the zebrafish model demonstrates that LMO1 
interacts synergistically with MYCN to drive HRNB (Wang et al., 2011). This 
model begs the question if LMO1 and MYCN interact similarly in human NB 
development. 
Animals models have proved a useful tool in studying many diseases, 
though there are generally expensive, time-consuming, and lack scalability. 
Researchers utilize primary cell models to address some of the animal model 
limitations and gain the ability to observe the cellular properties of tissues in vitro. 
In the case of NB, animal models have shown tumor formation in the 
overexpression of MYCN and LMO1 in NCC. The primary NCC model was 
developed to study the early stages of NB oncogenesis, assess the oncogenic 
drivers, and characterized NB metastasis. The primary NCC were isolated from 
the trunk neural tube of heterozygous p53+/- mice (embryonic day 9.5), and the 






et al. 2019; Kim, J. et al. 2003). The extracted cells were transduced with N-Myc-
IRES-GFP retrovirus and reintroduced into nude and C57BI/6 mice (Kawauchi et 
al., 2012). There was 100% tumor penetrance in the eight nude mice and six 
C57BI/6. NCC tumors were analyzed for chromosomal aberrations, which 
revealed chromosomal gains and losses analogous to human MYCN amplified 
NB (Olsen et al. 2019). The modification of murine neural crest cells to form 
neuroblastoma by the overexpression of MYCN provided the evidence we could 




















THE CREATION OF THE CELL LINE 
 A Human Neuroblastoma Model          
The overexpression of LMO1 and MYCN in clinically observed human 
tumors and their direct involvement in driving NB in animal and cell models 
makes these two genes rather appropriate to study in a human system. A 
popular human model for studying human diseases is the use of human stem 
cells, either induced pluripotent stem (IPSC) or embryonic stem cells (ESCs). 
IPSCs are reprogramed from adult cells to become pluripotent. The adult cell is 
obtained from an individual that has a disease and is studied to develop a 
patient-specific treatment. In the case of NB, there are examples of IPSC lines, 
but these cell lines carry the genetic mutations of the patient, which is 
advantageous in therapy design, but not for developmental research (Marin et al. 
2019). The advantage of ESCs is that they permit researchers to modify the 
human genome with the genes they wish to study and differentiate them into the 
cells or tissue of their research model. Our laboratory is primarily concerned with 
the development of neuroblastoma from neural crest cells, so ESC is the model 
that permits us to examine the role of LMO1 and MYCN in the human 









H1 Cell Line Design 
 
The construction of the cell line required the development of plasmid 
constructs that integrated LMO1 and MYCN into the H1 ESC genome and 
permitted controlled expression. The TET-3G plasmid (AAVS1 Puro Tet3G 
3xFLAG Twin Strep. Addgene catalog # 92099) was selected because of the 
homologous arms in the plasmid specific to the AAVS1 locus and the TET-ON 
inducible system. The homologous arm right is 837 bases and the homologous 
arm left is 804 bases these sequences are specific to the AAVS1 locus at human 
chromosome 19. The AAVS1 locus is popularly labeled the “safe harbor” as it 
allows reliable integration of genes by homology driven repair under CRISPR 
Cas9 modification (Sadelain, M., Papapetrou, E. P., & Bushman, F. D., 2011). 
This technique in the past been shown to be highly efficient in modifying hESC 
genomes, and experiments report low off-target alteration (Castaño et al., 2017). 
TET-ON is a gene regulatory system that allows for the reliable and tight 
expression of a gene in the presence of the molecule doxycycline – a small 
molecule demonstrated not to produce cytotoxic effects or unwanted 
differentiation of cells in gene therapy application (Das, A. T., Tenenbaum, L., & 










Isolation of Human LMO1 and MYCN Genes 
 
The LMO1 protein-encoding gene was isolated from 3-day old neural crest cells 
cDNA to design the TET-3G LMO1 construct for integration into the AAVS1 
locus.     
 
Figure 2. Agarose Gel of the LMO1 Gene. 
Isolated from Day 3 neural crest cell cDNA library maintained by the Garcia-
Castro laboratory. The products are 463 base pairs in length and are in lanes 2, 










The MYCN cDNA was isolated from the pCDNA3-HA-human W- MYCN 
(MYCN donor) plasmid to construct the TET-3G MYCN plasmid for integration to 
the AAVS1 locus. 
 
Figure 3. MYCN Donor Plasmid. 
The pCDNA3-HA human plasmid contained MYCN protein-coding sequence 








Figure 4. Agarose Gel of the MYCN Gene.  
Isolated from the MYCN donor plasmid. The products are 1392 bases and visible 
in lanes 2, 4, and 6. 
 
Creation of the TET-3G LMO1 and TET-3G MYCN Plasmids 
 
The intention for the modification of the AAVS1 locus was to have a 
heterogeneous integration of LMO1 and MYCN to chromosome 19. To 
accomplish this task, we created the LMO1 construct controlled by the TET-ON 







Figure 5. TET-3G LMO1 Plasmid.  
The LMO1 gene is regulated by the Tetracycline inducible system and flanked by 








Figure 6. TET-3G MYCN Plasmid. 
The MYCN gene is regulated by the Tetracycline inducible system and flanked 









Figure 7. Agarose Gel of TET-3G LMO1 and TET-3G MYCN Constructs.  
The TET-3G LMO1 is in lanes 1-4 the product for lanes 2-4 is approximately 7.1 
kb. The TET-3G MYCN is in lanes5-8 and lanes 5 and 7 are approximately 8kb 
which correspond with expected product sizes. 
 
Integration of TET-3G LMO1 into H1 hESC 
 
Once the constructs were formed and isolated from bacterial cultures, it 
was critical to validate the MYCN and LMO1 sequences before H1 hESC 
nucleofection. The MYCN construct revealed a 24 base pair deletion at the 494-
nucleotide position inside the MYCN coding region. The MYCN donor plasmid 
was sequenced, which reveal the same 24 base pair deletion. The LMO1 
construct contained a single nucleotide polymorphism that resulted in a silent 
mutation that did not alter the LMO1 protein. Based on the sequence analysis, 








Figure 8. TET-3G MYCN Sequence Alignment.  
The TET-3G MYCN has a 24 base pair deletion in the gene which was 
characterized from sequencing and Snap Gene alignment. 
 
 
Figure 9. TET-3G LMO1 Sequence Alignment.  
The TET-3G LMO1 construct contains a single nucleotide polymorphism that 











Figure 10. TET-3G LMO1 H1 hESC Sequence Alignment. 
The alignment displays a fragmented sequence of the LMO1 coding gene 


























DISCUSSION AND CONCLUSION 
 
 
Obstacles and Limitations 
The project, in principle, is straightforward, but the development of the cell 
line required multiple design modifications within a narrow time constraint. The 
development of the LMO1 and MYCN constructs occurred quickly in the project 
timeline, but of course, the MYCN mutation was identified once the construct was 
isolated from bacterial cultures and sequenced. The MYCN repair was 
complicated as the gene is 66% GC rich, and the region of the 24-base pair 
deletion contains 92% GC content. These GC dense areas inhibited our ability to 
modify the region with PCR as temperatures required for annealing were equal to 
or higher than the polymerase activation temperature. Several piece-wise PCR 
strategies were undertaken, but repair of the MYCN remained unsuccessful. An 
alternative strategy considered was using a vector building company to synthesis 
the MYCN gene; however, due to the GC content and size of our gene, 
companies were unable to synthesize the gene. To address the GC content and 
build a synthetic gene, I went through the MYCN gene and created synthetic 
sequences that replaced cystines and guanines with thymine and adenine but did 
not alter the protein sequence. This strategy proved to be expensive and outside 






 There was a necessity for the constructs have a fluorescent tag to permit 
screening and selection in the H1 hESC. The MYCN construct never proceeded 
to the fluorescent modification stage, but the LMO1 construct was created quickly 
and without issue. There were two fluorescent models for LMO1, the first utilizing 
an EGFP gene flanked by two loci of X-over P1 (loxP) sites. This model intended 
to identify the H1 hESC that contained LMO1 and depending on future 
experimental parameters; the EGFP could be removed. This construct was never 
synthesized in several Infusion strategies. The second model strategy integrates 
the EGFP gene into the Tet-3G LMO1 construct, which would permanently 
express EGFP in the H1 hESC. The EGFP expression was desirable for both 
selection as well as future tracing in developmental experiments if the cells were 
implanted into one of the Garcia-Castro animal models. The integration of the 
EGFP gene did appear successful in the sequence analysis of the gene. 
However, the transfection of the TET-3G LMO1 EGFP into HEK-293 cells did not 
produce a fluorescent signal. This test of the EGFP was conducted with the 
donor EGFP plasmid the gene was isolated from along with a commercial 
plasmid, both controls produced clear fluorescent signals. The attempts to 
develop a TET-3G LMO1 construct with a fluorescent marker were time-
consuming and unsuccessful, so I decided to continue the project with just the 
TET-3G LMO1 construct and screen the LMO1 sequence in less efficient manner 








 The MYCN gene on the TET-3G MYCN construct contained a 24-
nucleotide deletion at the 494-528 base pair region. To identify if the mutation 
was a result of the construct engineering, I sequenced the MYCN donor plasmid. 
The mutation was contained in the donor and was the source of the mutation. 
The next question that emerged from the sequence analysis was, did the 24-
base pair deletion corresponds to an isoform that has been characterized in 
cancer formation, particularly neuroblastoma. The mutated sequence was 
uploaded to the NCBI Basic Local Alignment Search Tool (BLAST) to examine 
the protein characteristics. The MYCN gene contained in the MYCN donor 
plasmid mapped onto the human MYCN gene but with a 96.99% identity match 
signifying this mutation has not been characterized previously and could not be 
integrated into our H1 hESC model in this form. The MYCN construct underwent 
many attempts to repair the gene using several subcloning strategies. Despite 
my best efforts, the MYCN gene contains the 24-base pair deletion in both the 
donor and the TET-3G MYCN plasmids. 
 
LMO1 Development 
 The isolation of the LMO1 gene was straightforward as I was able 
to extract it from the neural crest cell cDNA library maintained in the Garcia-
Castro lab. Sequencing of the LMO1 gene and analysis with NCBI BLASTX 






TET-3G LMO1 plasmid was a development, I repeated the same analysis, and 
the results were the same, so we set aside a sample of the bacterial stock for 
long-term storage and proceeded with the H1 hESC nucleofection with the TET-
3G LMO1 construct.  I maintained the H1 hESC for about a week to permit the 
nonintegrated plasmid to deteriorate so that analysis would only show sequence 
analysis from integrated LMO1. The sequence analysis revealed a fragmented 
sequence of the LMO1 gene along with the flanking sequence of the homologous 
arms of the TET-3G LMO1 plasmid. However, given that the sequence of the 
LMO1 gene was fragmented and weaker than the signal obtained from the 
homologous arms sequence suggest the integration occurred in a small subset of 
the ESCs, and therefore the cell population is a mixed colony. The establishment 
of the H1 hESC with the LMO1 cell line is essential for the development of our 
human NB model as LMO1 has been characterized as a significant oncogene in 
zebrafish and several GWAS in the United States, Europe, and China.  
 
Conclusion 
 The development of the TET-3G LMO1 H1 hESC is one component 
of the human model to understand the role of LMO1 and MYCN in 
neuroblastoma formation. Like with all scientific research, projects are never truly 
finished, and there are some immediate experiments I would continue if time 
permitted. The TET-3G LMO1 H1 ESC must undergo further colony screening to 






development of the LMO1 plus MYCN inducible cell line. Once the LMO1 line is 
stable, the next step will be to integrate the MYCN gene. Recently, there have 
been several plasmids containing human MYCN cDNA that has been donated to 
the company addgene. It would prove beneficial to locate the researchers that 
developed these plasmids and inquire about their function and gene composition; 
one of these plasmids may serve as the MYCN gene donor for our experiment. 
Once the cell line is established, the next component will be to express the LMO1 
and MYCN proteins with doxycycline treatments. It is important to mention that 
before purchasing the TET-3G plasmid, I conducted toxicity tests on H1 hESC 
with the doxycycline concentrations ranging from 0.25- 2 mg/ml over five days 
and observed no changes in morphology or impediment to survival. Following the 
doxycycline treatment to the LMO1 plus MYCN cell line and understanding the 
parameters needed to maintain H1 hESC morphology, the cells can undergo 
neural crest cell induction, in which the Garcia-Castro laboratory has an efficient 
and proven protocol. My role in the project was the development of the H1 ESC 
cell line, and given the parameters and obstacles we encountered, the members 
of the Garcia-Castro lab and I believe the development of the H1 hESC LMO1 










METHODS AND MATERIALS 
 
Plasmid Linearization and DNA Purification 
 
PCR linearized the AAVS1 Puro Tet3G 3xFLAG Twin Strep (TET-3G) plasmid 
with primers AAVS1 TET ON VEC forward and AAVS1 TET ON VEC reverse 
(Table 1).  
1. The PCR was conducted in a SimpliAmp™ Thermal Cycler, using 
Phusion™ High-Fidelity polymerase under reaction specific cycle 
conditions (see Table 1). 
 
2. The PCR product ran on a 1% agarose gel mixed with GelRed® Nucleic 
Acid Gel Stain and visualized in a Bio-Rad Gel DocTM XR+ Gel 
Documentation System.  
3. The PCR fragment was purified from the gel using the Zymoclean Gel 
DNA Recovery Kit.  
The PCR equipment and DNA purification process for LMO1, MYCN, and 
EGFP are identical to methods used in TET-3G purification. The only 










Cycling Conditions  
 
  One-time Initial denaturation: 95O C for 1 minute 
  
 35 cycles: Denature 95O C for 20 seconds 
     Annealing varied temperature for 10 seconds 












TET-3G VEC TET ON AAVS1 TET ON 64O C:10 sec Infusion 




hMYCN TET hMYCN TET 58O C: 15 sec Infusion 
AAVS1 EGFP 
donor 
CMV EGFP CMV EGFP 69O C: 25 sec Infusion 
Table 1. PCR Reactions. 
 
Cloning of LMO1 and MYCN into the TET-3G Plasmid 
 
1. The Vector and inserts were ligated using the Takara In-Fusion® cloning 
kit. The reaction formulations were performed with the Takara In-Fusion® 
Molar Ratio Calculator tool.  
2. The 10 ul cloning mixture was incubated for 15 minutes at 50O C.  
3. Following the ligation reaction, 2.5 ul of the TET-3G LMO1 and TET-3G 
MYCN were added to separate 50 ul of Stellar Super Competent cells, 
placed on ice for 30 minutes, and proceeded by 45 seconds of heat shock 






4. 500ul of 37O C SOC media was added to the transformation reaction and 
incubated at 37O C for 1 hour on the shaker.  
5. The cells were plated on LB ampicillin agar plates and grown for 14 hours 
at 37O C. Several bacterial colonies from both plasmids were picked and 
expanded in 2 ml of LB media containing ampicillin for 12-16 hours.  
6. A 600 ul sample taken from each 2 ml culture, and the DNA was extracted 
using a ZymoPURE™ Plasmid Miniprep Kit.  
7. Retrogen Inc sequenced the TET-3G LMO1 and TET-3G MYCN plasmids. 
8.  Based on sequence analysis, 10ul of the TET-3G LMO1 culture was 
added to 90 ml of LB liquid media containing 90 ul of ampicillin and was 
grown for 12 hours at 37O C on a shaker.  
9. The TET-3G LMO1 DNA was collected with the ZymoPURE™ Plasmid 
Midiprep Kit. 
 
Creating the TET-3G LMO1 EGFP Plasmid 
 
The TET-3G LMO1 plasmid was linearized by restriction digestion using the 
enzymes HPA1 and NSI1, incubated at 37O C for 12 hours. The TET-3G LMO1 
linear plasmid and EGFP fragment were ligated, verified, and expanded following 
the methods used in the TET 3G LMO1 plasmid development (shown above). 
H1 hESC Nucleofection and Colony Selection 
 
1. Human ESCs were cultured in mTSeR medium with Rho Kinase (ROCK)-






2. Cells were washed three times by Ca/Mg-Free PBS, digested by Accutase 
(Stem Cell Tech) for 5 minutes, and harvested in mTSeR medium with 
10uM ROCK-inhibitor.  
3. Cells were dispersed into single cells and counted. Cells at 1.4-1.6x106 
density are aliquoted into a 15ml conical tube for each nucleofection.  
4. Cells were spun down at 90 x g for 3min at RT.  
5. Cells were gently resuspended in 100ul of P3 Nucleofection Buffer 
(Lonza) containing a combination of plasmids up to 10% of the total 
volume (10ul max.). 15μg Cas9 plasmid, 15μg each sgRNA plasmid for 
wild-type Cas9, and 30μg TET-3G LMO1 were used for nucleofection—
the ratio of 1:1:2 (cas9: sgRNA: donor plasmid should always be 
maintained).  
6. The cells in P3 buffer +TET-3G LMO1 plasmids were nucleofected using 
the 4D-Nucleofector System (Lonza) using the CN-137 setting in single 
100ul-cuvettes (Lonza).  
7. Removed the cuvette and let the cells stand in the cuvette for 2-3mins in 
the hood after 2-3mins added 500ul of warm mTSeR (with Ri).  
 
8. Plate the cell in the Matrigel wells of a 6-well plate. 
 





































The creation of the TET-3G LMO1 H1 hESC line was established with the 
integration of the TET-ON and LMO1 DNA with the CRISPR Cas 9 gene-editing system. 
The homologs arm on the TET-3G LMO1 have sequence specificity to the AAVS1 




Modified by CRISPR Cas 9 homologous directed repair with the AAVS1 arms of the 
plasmid. The model represents a stand-in position for either the LMO1 or MYCN gene. 
However, the actual construct would contain only one of the genes, and heterozygous 

































































































AAVS1 Homologous Arms Sequence.  
The blue font corresponds to the homologous left arm of the TET-3G LMO1, and 







TET-3G LMO1 Homologous Arms Alignment.  
The alignment of the AAVS1 integration site with the TET-3G LMO1 plasmid 
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